Investigating Ex Vivo Animal Models to Test the Performance of Intravitreal Liposomal Drug Delivery Systems.
intravitreal
liposomes
ocular drug delivery
retinal explants
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
02 Jul 2021
02 Jul 2021
Historique:
received:
31
05
2021
revised:
25
06
2021
accepted:
25
06
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
11
8
2021
Statut:
epublish
Résumé
There is a strong need for innovative and efficient drug delivery systems for ocular therapy development. However, testing intravitreal drug delivery systems without using live animals is challenging. Ex vivo animal models offer an interesting alternative. We analyzed the potential of using fresh porcine eyes obtained from the local slaughterhouse as a model for testing the intravitreal biodistribution and retention of liposomes with or without polyethylene glycol (PEG) conjugation and with different surface charges. The histology of the eyes was analyzed to localize the liposomes, and it was found that liposomes with PEG absorbed rapidly on the retina (within 1 h), with positively charged and PEG-coated liposomes being retained for at least 24 h. In parallel, fluorophotometry was employed on intact eyes, to determine the pharmacokinetics of the fluorophore calcein, as a substitute for a small hydrophilic therapeutic compound. We found a 4.5-fold increase in the vitreous half-life of calcein loaded in liposomes, compared with the free solution. Retinal toxicity was addressed using murine-derived retinal explant cultures. Liposomes were non-toxic up to 500 µg/mL. Toxicity was observed at 5 mg/mL for anionic and cationic liposomes, with 2-fold and 2.5-fold increased photoreceptor cell death, respectively. Overall, we could show that important ocular drug delivery considerations such as pharmacokinetics and biodistribution can be estimated in ex vivo porcine eyes, and may guide subsequent in vivo experiments.
Identifiants
pubmed: 34371707
pii: pharmaceutics13071013
doi: 10.3390/pharmaceutics13071013
pmc: PMC8309192
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : PA1751/10-1
Références
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6991-9
pubmed: 26513505
Langmuir. 2013 Jul 23;29(29):9208-15
pubmed: 23837701
Int J Pharm. 2017 Apr 30;522(1-2):119-127
pubmed: 28232270
J Control Release. 2020 Dec 10;328:952-961
pubmed: 33091527
Eye (Lond). 2008 Oct;22(10):1214-22
pubmed: 18309340
Exp Eye Res. 2015 Aug;137:111-24
pubmed: 25975234
Biophys J. 2015 Nov 17;109(10):2171-81
pubmed: 26588575
Acta Ophthalmol. 2008 Jun;86(4):372-6
pubmed: 18028234
Prog Retin Eye Res. 2017 Mar;57:134-185
pubmed: 28028001
Invest Ophthalmol Vis Sci. 2007 May;48(5):2230-7
pubmed: 17460284
Methods Mol Biol. 2011;682:3-13
pubmed: 21057916
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E2997-E3006
pubmed: 29531030
J Chem Neuroanat. 2001 Nov;22(4):263-73
pubmed: 11719023
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3575-82
pubmed: 20164461
Medchemcomm. 2019 Feb 12;10(3):369-377
pubmed: 31015904
Behav Res Methods. 2021 Feb;53(1):167-187
pubmed: 32643061
Toxicol Res (Camb). 2017 Sep 15;6(6):947-957
pubmed: 30090555
Macromol Biosci. 2018 Feb;18(2):
pubmed: 29205853
Curr Drug Metab. 2014;15(9):882-92
pubmed: 25658127
Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1338-44
pubmed: 27002293
Nanomaterials (Basel). 2021 Jan 12;11(1):
pubmed: 33445545
J Neurochem. 2009 Feb;108(3):796-810
pubmed: 19187097
Biochimie. 2013 Nov;95(11):2018-33
pubmed: 23871914
Invest Ophthalmol Vis Sci. 2009 Feb;50(2):814-9
pubmed: 18806295
Pharmaceutics. 2019 Jul 31;11(8):
pubmed: 31370346
Ophthalmology. 2007 Dec;114(12):2179-82
pubmed: 18054637
Int J Pharm. 2017 Apr 30;522(1-2):90-97
pubmed: 28267579
J Microencapsul. 1996 Jul-Aug;13(4):473-80
pubmed: 8808783
Z Anat Entwicklungsgesch. 1973 Oct 31;142(2):219-38
pubmed: 4781863
Mol Pharm. 2017 Feb 6;14(2):423-430
pubmed: 27936751
Int J Pharm. 2020 Feb 25;576:118987
pubmed: 31870961
J Control Release. 2012 Jul 20;161(2):628-34
pubmed: 22289436
Ophthalmology. 1993 Nov;100(11):1640-4
pubmed: 8233389
Molecules. 2021 Mar 09;26(5):
pubmed: 33803405
Int J Pharm. 2018 Jul 30;546(1-2):20-30
pubmed: 29753904
J Biomed Mater Res B Appl Biomater. 2005 Feb 15;72(2):292-8
pubmed: 15486967
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):215-26
pubmed: 25603198
J Vis Exp. 2020 Nov 25;(165):
pubmed: 33311434
J Neurosci. 1999 Oct 15;19(20):9098-106
pubmed: 10516327
Pharm Res. 2006 Aug;23(8):1850-6
pubmed: 16841197
Int Ophthalmol. 1988;12(2):105-7
pubmed: 3229898